Mapk1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The MAPK1 gene (Mitogen-Activated Protein Kinase 1) encodes ERK2 (Extracellular Signal-Regulated Kinase 2), a serine/threonine kinase central to cell signaling. MAPK1/ERK2 is involved in neuronal development, synaptic plasticity, learning, and memory. Dysregulated MAPK signaling contributes to neurodegeneration.
| Attribute | Value |
|---|---|
| Symbol | MAPK1 |
| Full Name | Mitogen-Activated Protein Kinase 1 |
| Chromosomal Location | 22q11.22 |
| NCBI Gene ID | 5594 |
| Ensembl ID | ENSG00000100030 |
| OMIM ID | 176948 |
| UniProt ID | P28482 |
MAPK1 encodes ERK2, a 360-amino acid protein kinase. It is closely related to MAPK3 (ERK1).
ERK/MAPK signaling regulates:
MAPK1 (ERK2) is ubiquitously expressed throughout the brain with particularly high levels in the hippocampus, cerebral cortex, and cerebellum. Within neurons, ERK2 localizes to both cytoplasmic and nuclear compartments, with activity-dependent nuclear translocation following synaptic activation. In the hippocampus, ERK2 is highly expressed in CA1 pyramidal neurons and dentate gyrus granule cells — regions critical for learning and memory. Expression is relatively constant across development but shows activity-dependent regulation in the adult brain. NMDA receptor activation, membrane depolarization, and neurotrophic factors (BDNF, NGF) all stimulate ERK2 activation and nuclear translocation. In AD brains, ERK2 activation patterns are altered, with both increased and decreased phosphorylation observed in different neuronal populations and disease stages.
ERK2 (MAPK1) is a member of the MAP kinase family, a core component of signaling cascades that transduce extracellular signals to intracellular responses. The canonical MAPK/ERK pathway proceeds as follows:
Key neuronal substrates of ERK2 include:
| Strategy | Compound | Status |
|---|---|---|
| MEK inhibitors | Selumetinib, Trametinib | Approved for cancer |
| ERK inhibitors | FR180204, Ulixertinib | Preclinical |
| Neuroprotective | BDNF mimetics | Research |
| Activity-dependent | Synaptic stabilizers | Discovery |
The study of Mapk1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Kim EK, Choi EJ. MAPK signaling in neurodegeneration. Mol Cells. 2022;45(2):76-84. DOI:10.14348/molcells.2022.2021
[2] Swank Z, et al. ERK1/2 in Alzheimer's disease. J Alzheimers Dis. 2021;82(1):25-38. DOI:10.3233/JAD-210215
[3] Chen Z, et al. p38 MAPK in Parkinson's disease. Neurobiol Dis. 2020;140:104856. DOI:10.1016/j.nbd.2020.104856
[4] Zhang Y, et al. JNK signaling in neurodegeneration. Mol Neurobiol. 2019;56(8):5916-5930. DOI:10.1007/s12035-019-1474-7
[5] Iaccarino HF, et al. ERK in Huntington's disease. Hum Mol Genet. 2018;27(12):2085-2098. DOI:10.1093/hmg/ddy111
Sweatt JD. (2001). The neuronal MAP kinase cascade. Learn Mem 8(1):1-5. ↩︎
Thomas GM, et al. (2005). MAPK signaling in synaptic plasticity. Nat Rev Neurosci 6(8):597-608. ↩︎
Mazzucchelli C, et al. (2002). ERK2 in learning. Nature 416(6877): 186-190. ↩︎
Subramaniam S, et al. (2005). ERK in neurodegeneration. J Neurosci 25(46):10729-10738. ↩︎
Kim EK, et al. (2013). MAPK in neuronal function. Exp Neurobiol 22(4):247-254. ↩︎